Hellmut Augustin

Prof. Dr. Hellmut Augustin


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
HAHellmut Augustin
Hellmut Augustin
GKGou Young Koh
Gou Young Koh
GTGavin Thurston
Gavin Thurston
KAKari Alitalo
Kari Alitalo

24 March 2021 in Nature
Verified
Journal Article
Open access
PDF file
DPDominik Pfister
Dominik Pfister
NNNicolás Gonzalo Núñez
Nicolás Gonzalo Núñez
RPRoser Pinyol
Roser Pinyol
OGOlivier Govaere
Olivier Govaere
MPMatthias Pinter
Matthias Pinter
MHMathias Heikenwälder
Mathias Heikenwälder
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH–HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+T cells or TNF neutralization, suggesting that CD8+T cells help to induce NASH–HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH–HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.

5 February 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
UFUlrike Fiedler
Ulrike Fiedler
YRYvonne Reiss
Yvonne Reiss
MSMarion Scharpfenecker
Marion Scharpfenecker
VGVerena Grunow
Verena Grunow
SKStefanie Koidl
Stefanie Koidl
HAHellmut Augustin
Hellmut Augustin

25 August 2017 in Science
Verified
Journal Article
Closed access
PDF file
HAHellmut Augustin
Hellmut Augustin
GKGou Young Koh
Gou Young Koh
Dynamic vascular surfaces: Blood vessels have long been considered as passive conduits for blood and circulating cells that, at best, respond to exogenous cytokines. However, recent work has shown that blood vessels serve as a highly dynamic interface between the circulation and tissues. Augustin et al. review molecular mechanisms of vascular development and function in different organs. Differentiated endothelial cells develop as a sort of cobblestone monolayer to form one of the largest surfaces within the body. Vascular control of the tissue microenvironment is vital, not only for normal tissue development and homeostasis, but also for disease states ranging from inflammation to cancer. Science , this issue p. eaal2379

1 June 2004 in Blood
Verified
Journal Article
Closed access
UFUlrike Fiedler
Ulrike Fiedler
MSMarion Scharpfenecker
Marion Scharpfenecker
SKStefanie Koidl
Stefanie Koidl
AHAnja Hegen
Anja Hegen
VGVerena Grunow
Verena Grunow
HAHellmut Augustin
Hellmut Augustin
The angiopoietins Ang-1 and Ang-2 have been identified as ligands with opposing functions of the receptor tyrosine kinase Tie-2 regulating endothelial cell survival and vascular maturation. Ang-1 acts in a paracrine agonistic manner, whereas Ang-2 appears to act primarily as an autocrine antagonistic regulator. To shed further light on the complexity of autocrine/paracrine agonistic/antagonistic functions of the angiopoietin/Tie-2 system, we have studied Ang-2 synthesis and secretion in different populations of wild-type and retrovirally Ang-2–transduced endothelial cells. Endogenous and overexpressed endothelial cell Ang-2 is expressed in a characteristic granular pattern indicative of a cytoplasmic storage granule. Light and electron microscopic double staining revealed Ang-2 colocalization with von Willebrand factor, identifying Ang-2 as a Weibel-Palade body molecule. Costaining with P-selectin showed that storage of Ang-2 and P-selectin in Weibel-Palade bodies is mutually exclusive. Stored Ang-2 has a long half-life of more than 18 hours and can be secreted within minutes of stimulation (eg, by phorbol 12-myristate 13-acetate [PMA], thrombin, and histamine). Collectively, the identification of Ang-2 as a stored, rapidly available molecule in endothelial cells strongly suggests functions of the angiopoietin/Tie-2 system beyond the established roles during angiogenesis likely to be involved in rapid vascular homeostatic reactions such as inflammation and coagulation.

1 December 2006 in Trends in Immunology
Verified
Journal Article
Closed access
UFUlrike Fiedler
Ulrike Fiedler
HAHellmut Augustin
Hellmut Augustin